Function-oriented development of CXCR4 antagonists as selective human immunodeficiency virus (HIV)-1 entry inhibitors

Journal of Medicinal Chemistry

Volumn 58, Issue 3, 2015, Pages 1452-1465

  Wu, Chien Huang ^a   Wang, Chuan Jen ^b   Chang, Chun Ping ^a   Cheng, Yung Chi ^b   Song, Jen Shin ^a   Jan, Jiing Jyh ^a   Chou, Ming Chen ^a   Ke, Yi Yu ^a   Ma, Jing ^c   Wong, Ying Chieh ^a   Hsieh, Tsung Chih ^a   Tien, Yun Chen ^b   Gullen, Elizabeth A ^b   Lo, Chen Fu ^a   Cheng, Chia Yi ^a   Liu, Yu Wei ^a   Sadani, Amit A ^a   Tsai, Chia Hua ^a   Hsieh, Hsin Pang ^a   Tsou, Lun K ^a   Shia, Kak Shan ^a   more..

^a NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

6 METHOXY N 4 PIPERIDIN 4 YL N 2 [4 [(3 PIPERIDIN 1 YL PROPYLAMINO) METHYL] BENZYL] QUINAZOLINE 2,4 DIAMINE; 6,7 DIMETHOXY N 4 PIPERIDIN 4 YL N 2 [4 [(3 PIPERIDIN 1 YL PROPYLAMINO) METHYL] BENZYL] QUINAZOLINE 2,4 DIAMINE; 7 METHOXY N 4 PIPERIDIN 4 YL N 2 [4 [(3 PIPERIDIN 1 YL PROPYLAMINO) METHYL] BENZYL] QUINAZOLINE 2,4 DIAMINE; CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR4 ANTAGONIST; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; N 2 [4 [(3 CYCLOHEPTYLAMINO PROPYLAMINO) METHYL] BENZYL] 6 METHOXY N 4 PIPERIDIN 4 YL QUINAZOLINE 2,4 DIAMINE; N 2 [4 [(3 CYCLOHEPTYLAMINO PROPYLAMINO) METHYL] BENZYL] 6,7 METHOXY N 4 PIPERIDIN 4 YL QUINAZOLINE 2,4 DIAMINE; N 2 [4 [(3 CYCLOHEPTYLAMINO PROPYLAMINO) METHYL] BENZYL] 7 METHOXY N 4 PIPERIDIN 4 YL QUINAZOLINE 2,4 DIAMINE; N 2 [4 [(3 CYCLOHEXYLAMINO PROPYLAMINO) METHYL] BENZYL] 6 METHOXY N 4 PIPERIDIN 4 YL QUINAZOLINE 2,4 DIAMINE; N 2 [4 [(3 CYCLOHEXYLAMINO PROPYLAMINO) METHYL] BENZYL] 6,7 DIMETHOXY N 4 PIPERIDIN 4 YL QUINAZOLINE 2,4 DIAMINE; N 2 [4 [(3 CYCLOHEXYLAMINO PROPYLAMINO) METHYL] BENZYL] 7 METHOXY N 4 PIPERIDIN 4 YL QUINAZOLINE 2,4 DIAMINE; N CYCLOHEXYL N' [2 [4 [(2 PIPERAZIN 1 YL 9H PURIN 6 YLAMINO) METHYL] PHENY] ETHYL] PROPANE 1,3 DIAMINE; N CYCLOHEXYL N' [3 [(2 PIPERAZIN 1 YL 9H PURIN 6 YLAMINO) METHYL] BENZYL] PROPANE 1,3 DIAMINE; N CYCLOHEXYL N' [4 [(2 PIPERAZIN 1 YL 9 H PURIN 6 YLAMINO)METHYL] BENZYL] PROPANE 1,3 DIAMINE; N CYCLOHEXYL N' [4 [(9 METHYL 2 PIPERAZIN 1 YL 9 H PURIN 6 YLAMINO) METHYL] BENZYL] PROPANE 1,3 DIAMINE; N CYCLOHEXYL N' [4 [2 (2 PIPERAZIN 1 YL 9H PURIN 6 YLAMINO) ETHYL] BENZYL] PROPANE 1,3 DIAMINE; N CYCLOHEXYL N' [4 [[9 METHYL 2 (4 METHYL PIPERAZIN 1 YL) 9 H PURIN 6 YLAMINO] METHYL] BENZYL] PROPANE 1,3 DIAMINE; N CYCLOHEXYL N' [5 [(2 PIPERAZIN 1 YL 9H PURIN 6 YLAMINO)METHYL] PYRIDIN 3 YLMETHYL] PROPANE 1,3 DIAMINE; N CYCLOHEXYL N' [6 [(2 PIPERAZIN 1 YL 9H PURIN 6 YLAMINO)METHYL] PYRIDIN 2 YLMETHYL] PROPANE 1,3 DIAMINE; N CYCLOHEXYL N' [6 [(2 PIPERAZIN 1 YL 9H PURIN 6 YLAMINO)METHYL] PYRIDIN 3 YLMETHYL] PROPANE 1,3 DIAMINE; N [4 [(2 [4,4 '] BIPIPERIDINYL 1 YL 9H PURIN 6 YLAMINO) METHYL] BENZYL] N' CYCLOHEXYL PROPANE1,3 DIAMINE; PLERIXAFOR; STROMAL CELL DERIVED FACTOR 1ALPHA; UNCLASSIFIED DRUG; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; CXCR4 PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG DESIGN; DRUG IDENTIFICATION; DRUG INHIBITION; DRUG POTENCY; DRUG SELECTIVITY; EC50; EMBRYO; HOST CELL; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IC50; MALE; MOUSE; NONHUMAN; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CELL LINE; CHEMICAL STRUCTURE; CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; HIV INFECTIONS; METABOLISM; MICROBIAL SENSITIVITY TEST; MOLECULAR DYNAMICS; STRUCTURE ACTIVITY RELATION; SYNTHESIS; VIROLOGY; VIRUS ENTRY;

ANIMALS; CCR5 RECEPTOR ANTAGONISTS; CELL LINE; DOSE-RESPONSE RELATIONSHIP, DRUG; HIV FUSION INHIBITORS; HIV INFECTIONS; HIV-1; HUMANS; MALE; MICE; MICE, INBRED C57BL; MICROBIAL SENSITIVITY TESTS; MOLECULAR DYNAMICS SIMULATION; MOLECULAR STRUCTURE; RECEPTORS, CXCR4; STRUCTURE-ACTIVITY RELATIONSHIP; VIRUS INTERNALIZATION;

EID: 84922779010     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm501772w     Document Type: Article

References (50)

1. Montaner, J. S.; Hogg, R.; Wood, E.; Kerr, T.; Tyndall, M.; Levy, A. R.; Harrigan, P. R. The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic Lancet 2006, 368, 531-6
2. Yeni, P. G.; Hammer, S. M.; Carpenter, C. C.; Cooper, D. A.; Fischl, M. A.; Gatell, J. M.; Gazzard, B. G.; Hirsch, M. S.; Jacobsen, D. M.; Katzenstein, D. A.; Montaner, J. S.; Richman, D. D.; Saag, M. S.; Schechter, M.; Schooley, R. T.; Thompson, M. A.; Vella, S.; Volberding, P. A. Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel JAMA 2002, 288, 222-35
3. Feng, Y.; Broder, C. C.; Kennedy, P. E.; Berger, E. A. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor Science 1996, 272, 872-7
4. Deng, H.; Liu, R.; Ellmeier, W.; Choe, S.; Unutmaz, D.; Burkhart, M.; Di Marzio, P.; Marmon, S.; Sutton, R. E.; Hill, C. M.; Davis, C. B.; Peiper, S. C.; Schall, T. J.; Littman, D. R.; Landau, N. R. Identification of a major co-receptor for primary isolates of HIV-1 Nature 1996, 381, 661-6
5. Trkola, A.; Dragic, T.; Arthos, J.; Binley, J. M.; Olson, W. C.; Allaway, G. P.; Cheng-Mayer, C.; Robinson, J.; Maddon, P. J.; Moore, J. P. CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5 Nature 1996, 384, 184-7
6. Dragic, T.; Litwin, V.; Allaway, G. P.; Martin, S. R.; Huang, Y.; Nagashima, K. A.; Cayanan, C.; Maddon, P. J.; Koup, R. A.; Moore, J. P.; Paxton, W. A. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5 Nature 1996, 381, 667-73
7. Alkhatib, G.; Combadiere, C.; Broder, C. C.; Feng, Y.; Kennedy, P. E.; Murphy, P. M.; Berger, E. A. CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1 Science 1996, 272, 1955-8
8. Choe, H.; Farzan, M.; Sun, Y.; Sullivan, N.; Rollins, B.; Ponath, P. D.; Wu, L.; Mackay, C. R.; LaRosa, G.; Newman, W.; Gerard, N.; Gerard, C.; Sodroski, J. The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates Cell 1996, 85, 1135-48
9. Wilen, C. B.; Tilton, J. C.; Doms, R. W. Molecular mechanisms of HIV entry Adv. Exp. Med. Biol. 2012, 726, 223-42
10. Williams, I. G. Enfuvirtide (Fuzeon): the first fusion inhibitor Int. J. Clin. Pract. 2003, 57, 890-7
11. Fletcher, C. V. Enfuvirtide, a new drug for HIV infection Lancet 2003, 361, 1577-8
12. Gulick, R. M.; Lalezari, J.; Goodrich, J.; Clumeck, N.; DeJesus, E.; Horban, A.; Nadler, J.; Clotet, B.; Karlsson, A.; Wohlfeiler, M.; Montana, J. B.; McHale, M.; Sullivan, J.; Ridgway, C.; Felstead, S.; Dunne, M. W.; van der Ryst, E.; Mayer, H.; Teams, M. S. Maraviroc for previously treated patients with R5 HIV-1 infection N. Engl. J. Med. 2008, 359, 1429-41
13. Westby, M.; Lewis, M.; Whitcomb, J.; Youle, M.; Pozniak, A. L.; James, I. T.; Jenkins, T. M.; Perros, M.; van der Ryst, E. Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir J. Virol. 2006, 80, 4909-20
14. Muller, A.; Homey, B.; Soto, H.; Ge, N.; Catron, D.; Buchanan, M. E.; McClanahan, T.; Murphy, E.; Yuan, W.; Wagner, S. N.; Barrera, J. L.; Mohar, A.; Verastegui, E.; Zlotnik, A. Involvement of chemokine receptors in breast cancer metastasis Nature 2001, 410, 50-6
15. Balkwill, F. Cancer and the chemokine network Nat. Rev. Cancer 2004, 4, 540-50
16. Balkwill, F. The significance of cancer cell expression of the chemokine receptor CXCR4 Semin. Cancer Biol. 2004, 14, 171-9
17. Arnolds, K. L.; Spencer, J. V. CXCR4: a virus's best friend? Infect., Genet. Evol. 2014, 25, 146-56
18. Tamamis, P.; Floudas, C. A. Elucidating a key component of cancer metastasis: CXCL12 (SDF-1alpha) binding to CXCR4 J. Chem. Inf. Model. 2014, 54, 1174-88
19. Connor, R. I.; Sheridan, K. E.; Ceradini, D.; Choe, S.; Landau, N. R. Change in coreceptor use correlates with disease progression in HIV-1- individuals J. Exp Med. 1997, 185, 621-8
20. Raymond, S.; Delobel, P.; Mavigner, M.; Cazabat, M.; Encinas, S.; Souyris, C.; Bruel, P.; Sandres-Saune, K.; Marchou, B.; Massip, P.; Izopet, J. CXCR4-using viruses in plasma and peripheral blood mononuclear cells during primary HIV-1 infection and impact on disease progression AIDS 2010, 24, 2305-12
21. Sucupira, M. C.; Sanabani, S.; Cortes, R. M.; Giret, M. T.; Tomiyama, H.; Sauer, M. M.; Sabino, E. C.; Janini, L. M.; Kallas, E. G.; Diaz, R. S. Faster HIV-1 disease progression among Brazilian individuals recently infected with CXCR4-utilizing strains PLoS One 2012, 7, e30292
22. Schuitemaker, H.; Koot, M.; Kootstra, N. A.; Dercksen, M. W.; de Goede, R. E.; van Steenwijk, R. P.; Lange, J. M.; Schattenkerk, J. K.; Miedema, F.; Tersmette, M. Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus population J. Virol. 1992, 66, 1354-60
23. Grande, F.; Garofalo, A.; Neamati, N. Small molecules anti-HIV therapeutics targeting CXCR4 Curr. Pharm. Des 2008, 14, 385-404
24. Bleul, C. C.; Farzan, M.; Choe, H.; Parolin, C.; Clark-Lewis, I.; Sodroski, J.; Springer, T. A. The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry Nature 1996, 382, 829-33
25. Arenzana-Seisdedos, F.; Virelizier, J. L.; Rousset, D.; Clark-Lewis, I.; Loetscher, P.; Moser, B.; Baggiolini, M. HIV blocked by chemokine antagonist Nature 1996, 383, 400
26. Signoret, N.; Oldridge, J.; Pelchen-Matthews, A.; Klasse, P. J.; Tran, T.; Brass, L. F.; Rosenkilde, M. M.; Schwartz, T. W.; Holmes, W.; Dallas, W.; Luther, M. A.; Wells, T. N.; Hoxie, J. A.; Marsh, M. Phorbol esters and SDF-1 induce rapid endocytosis and down modulation of the chemokine receptor CXCR4 J. Cell Biol. 1997, 139, 651-64
27. Donzella, G. A.; Schols, D.; Lin, S. W.; Este, J. A.; Nagashima, K. A.; Maddon, P. J.; Allaway, G. P.; Sakmar, T. P.; Henson, G.; De Clercq, E.; Moore, J. P. AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor Nat. Med. 1998, 4, 72-7
28. Skerlj, R. T.; Bridger, G. J.; Kaller, A.; McEachern, E. J.; Crawford, J. B.; Zhou, Y.; Atsma, B.; Langille, J.; Nan, S.; Veale, D.; Wilson, T.; Harwig, C.; Hatse, S.; Princen, K.; De Clercq, E.; Schols, D. Discovery of novel small molecule orally bioavailable C-X-C chemokine receptor 4 antagonists that are potent inhibitors of T-tropic (X4) HIV-1 replication J. Med. Chem. 2010, 53, 3376-88
29. Wu, B.; Chien, E. Y.; Mol, C. D.; Fenalti, G.; Liu, W.; Katritch, V.; Abagyan, R.; Brooun, A.; Wells, P.; Bi, F. C.; Hamel, D. J.; Kuhn, P.; Handel, T. M.; Cherezov, V.; Stevens, R. C. Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists Science 2010, 330, 1066-71
30. Tamamis, P.; Floudas, C. A. Molecular recognition of CXCR4 by a dual tropic HIV-1 gp120 V3 loop Biophys. J. 2013, 105, 1502-14
31. Debnath, B.; Xu, S.; Grande, F.; Garofalo, A.; Neamati, N. Small molecule inhibitors of CXCR4 Theranostics 2013, 3, 47-75
32. Choi, W. T.; Duggineni, S.; Xu, Y.; Huang, Z.; An, J. Drug discovery research targeting the CXC chemokine receptor 4 (CXCR4) J. Med. Chem. 2012, 55, 977-94
33. Wu, C. H.; Chang, C. P.; Song, J. S.; Jan, J. J.; Chou, M. C.; Wu, S. H.; Yeh, K. C.; Wong, Y. C.; Hsieh, C. J.; Chen, C. T.; Kao, T. T.; Wu, S. Y.; Yeh, C. F.; Tseng, C. T.; Chao, Y. S.; Shia, K. S. Discovery of novel stem cell mobilizers that target the CXCR4 receptor ChemMedChem 2012, 7, 209-12
34. Choi, W. T.; Kumar, S.; Madani, N.; Han, X.; Tian, S.; Dong, C. Z.; Liu, D.; Duggineni, S.; Yuan, J.; Sodroski, J. G.; Huang, Z.; An, J. A novel synthetic bivalent ligand to probe chemokine receptor CXCR4 dimerization and inhibit HIV-1 entry Biochemistry 2012, 51, 7078-86
35. Tian, S.; Choi, W. T.; Liu, D.; Pesavento, J.; Wang, Y.; An, J.; Sodroski, J. G.; Huang, Z. Distinct functional sites for human immunodeficiency virus type 1 and stromal cell-derived factor 1alpha on CXCR4 transmembrane helical domains J. Virol. 2005, 79, 12667-73
36. Brelot, A.; Heveker, N.; Montes, M.; Alizon, M. Identification of residues of CXCR4 critical for human immunodeficiency virus coreceptor and chemokine receptor activities J. Biol. Chem. 2000, 275, 23736-44
37. Choi, W. T.; Tian, S.; Dong, C. Z.; Kumar, S.; Liu, D.; Madani, N.; An, J.; Sodroski, J. G.; Huang, Z. Unique ligand binding sites on CXCR4 probed by a chemical biology approach: implications for the design of selective human immunodeficiency virus type 1 inhibitors J. Virol. 2005, 79, 15398-404
38. Chabot, D. J.; Zhang, P. F.; Quinnan, G. V.; Broder, C. C. Mutagenesis of CXCR4 identifies important domains for human immunodeficiency virus type 1 X4 isolate envelope-mediated membrane fusion and virus entry and reveals cryptic coreceptor activity for R5 isolates J. Virol. 1999, 73, 6598-609
39. Zhou, N.; Luo, Z.; Luo, J.; Liu, D.; Hall, J. W.; Pomerantz, R. J.; Huang, Z. Structural and functional characterization of human CXCR4 as a chemokine receptor and HIV-1 co-receptor by mutagenesis and molecular modeling studies J. Biol. Chem. 2001, 276, 42826-33
40. Brelot, A.; Heveker, N.; Adema, K.; Hosie, M. J.; Willett, B.; Alizon, M. Effect of mutations in the second extracellular loop of CXCR4 on its utilization by human and feline immunodeficiency viruses J. Virol. 1999, 73, 2576-86
41. Burns, J. M.; Summers, B. C.; Wang, Y.; Melikian, A.; Berahovich, R.; Miao, Z.; Penfold, M. E.; Sunshine, M. J.; Littman, D. R.; Kuo, C. J.; Wei, K.; McMaster, B. E.; Wright, K.; Howard, M. C.; Schall, T. J. A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development J. Exp. Med. 2006, 203, 2201-13
42. Zabel, B. A.; Wang, Y.; Lewen, S.; Berahovich, R. D.; Penfold, M. E.; Zhang, P.; Powers, J.; Summers, B. C.; Miao, Z.; Zhao, B.; Jalili, A.; Janowska-Wieczorek, A.; Jaen, J. C.; Schall, T. J. Elucidation of CXCR7-mediated signaling events and inhibition of CXCR4-mediated tumor cell transendothelial migration by CXCR7 ligands J. Immunol. 2009, 183, 3204-11
43. Crump, M. P.; Gong, J. H.; Loetscher, P.; Rajarathnam, K.; Amara, A.; Arenzana-Seisdedos, F.; Virelizier, J. L.; Baggiolini, M.; Sykes, B. D.; Clark-Lewis, I. Solution structure and basis for functional activity of stromal cell-derived factor-1; dissociation of CXCR4 activation from binding and inhibition of HIV-1 EMBO J. 1997, 16, 6996-7007
44. Paintsil, E.; Dutschman, G. E.; Hu, R.; Grill, S. P.; Lam, W.; Baba, M.; Tanaka, H.; Cheng, Y. C. Intracellular metabolism and persistence of the anti-human immunodeficiency virus activity of 2',3'-didehydro-3'-deoxy-4'-ethynylthymidine, a novel thymidine analog Antimicrob. Agents Chemother. 2007, 51, 3870-9
45. Brooks, B. R.; Brooks, C. L., III; Mackerell, A. D., Jr.; Nilsson, L.; Petrella, R. J.; Roux, B.; Won, Y.; Archontis, G.; Bartels, C.; Boresch, S.; Caflisch, A.; Caves, L.; Cui, Q.; Dinner, A. R.; Feig, M.; Fischer, S.; Gao, J.; Hodoscek, M.; Im, W.; Kuczera, K.; Lazaridis, T.; Ma, J.; Ovchinnikov, V.; Paci, E.; Pastor, R. W.; Post, C. B.; Pu, J. Z.; Schaefer, M.; Tidor, B.; Venable, R. M.; Woodcock, H. L.; Wu, X.; Yang, W.; York, D. M.; Karplus, M. CHARMM: the biomolecular simulation program J. Comput. Chem. 2009, 30, 1545-614
46. Berendsen, H. J. C.; van der Spoel, D.; van Drunen, R. GROMACS: a message-passing parallel molecular dynamics implementation Comput. Phys. Commun. 1995, 91, 43-56
47. Hess, B.; Kutzner, C.; van der Spoel, D.; Lindahl, E. GROMACS 4: algorithms for highly efficient, load-balanced, and scalable molecular simulation J. Chem. Theory Comput. 2008, 4, 435-47
48. Schuttelkopf, A. W.; van Aalten, D. M. PRODRG: a tool for high-throughput crystallography of protein-ligand complexes Acta Crystallogr., Sect. D: Biol. Crystallogr. 2004, 60, 1355-63
49. Chiu, S. W.; Pandit, S. A.; Scott, H. L.; Jakobsson, E. An improved united atom force field for simulation of mixed lipid bilayers J. Phys. Chem. B 2009, 113, 2748-63
50. Hess, B.; Bekker, H.; Berendsen, H. J. C.; Fraaije, J. G. E. M. LINCS: a linear constraint solver for molecular simulations J. Comput. Chem. 1997, 18, 1463-72